Transform Wealth LLC Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Transform Wealth LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 10.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,354 shares of the medical research company’s stock after buying an additional 131 shares during the period. Transform Wealth LLC’s holdings in Amgen were worth $353,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. XTX Topco Ltd acquired a new stake in Amgen during the second quarter valued at approximately $661,000. Certified Advisory Corp raised its position in shares of Amgen by 16.0% during the 2nd quarter. Certified Advisory Corp now owns 1,460 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 201 shares in the last quarter. Steel Grove Capital Advisors LLC lifted its stake in Amgen by 5.8% during the second quarter. Steel Grove Capital Advisors LLC now owns 1,357 shares of the medical research company’s stock worth $424,000 after purchasing an additional 74 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in Amgen by 74.2% in the second quarter. Public Sector Pension Investment Board now owns 20,647 shares of the medical research company’s stock worth $6,451,000 after purchasing an additional 8,795 shares during the period. Finally, Evergreen Capital Management LLC increased its stake in Amgen by 2.5% during the second quarter. Evergreen Capital Management LLC now owns 9,057 shares of the medical research company’s stock valued at $2,830,000 after purchasing an additional 225 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 1.0 %

Amgen stock opened at $274.81 on Wednesday. The firm has a market cap of $147.72 billion, a price-to-earnings ratio of 35.19, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm’s 50 day moving average price is $272.95 and its two-hundred day moving average price is $306.92. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the previous year, the firm posted $4.96 EPS. The company’s quarterly revenue was up 23.2% on a year-over-year basis. On average, research analysts predict that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is currently 115.24%.

Analyst Ratings Changes

Several research firms have recently commented on AMGN. Royal Bank of Canada decreased their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Wolfe Research began coverage on Amgen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Citigroup cut their price objective on shares of Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.